6 In 10 People Will Develop Kidney Disease – Screening Now Recommended …Forbes… kidney disease, the study found a 33.6-percent risk of moderate-severe kidney disease; an 11.5-percent risk of stage 4 or severe kidney disease; and a 3.6-percent risk …
Music Calendar for Aug. 2, 2013 – Casper Star-Tribune Online
Music Calendar for Aug. 2, 2013Casper Star-Tribune Online10 at the Casper Events Center. Tickets: $35, available at 800-442-2256 or www.CasperEventsCenter.com. * Music & Poetry: Roy and India Hayford at 7:30 p.m. AUG. 12 at Metro Coffee Company, 24…
Newspaper Uncovers HHS Report of 'Dead' Patient Waking Up at Start of Organ … – Legal Examiner
|
Newspaper Uncovers HHS Report of ‘Dead’ Patient Waking Up at Start of Organ …
Legal Examiner They were also ordered to hire a consulting neurologist to teach staff how to accurately diagnose brain death. Sadly, Collen Burns committed suicide in January, 2011. Tags: doctor error, malpractice, malpractice attorney, misdiagnosis, organ transplant … |
Bigger Lungs Tied To Higher Success Rate Of Transplants: Could A Person's … – Medical Daily
Laboratory Equipment |
Bigger Lungs Tied To Higher Success Rate Of Transplants: Could A Person’s …
Medical Daily “An unresolved question in the field of lung transplantation is how the size of the donor lungs relative to the recipient affects transplant success,” said Eberlain, who is a clinical assistant professor in internal medicine at the University of Iowa … Bigger Lungs May Be Better for TransplantsNewswise (press release) For Lung Transplant, Researchers Surprised to Learn Bigger Appears to Be BetterScience Daily (press release) Lung transplant patients may fare better with larger organs – using a …Big News Network.com Headlines & Global News all 7 news articles » |
Answers About Rheumatoid Arthritis, Part 3 – New York Times
Answers About Rheumatoid Arthritis, Part 3New York TimesThese include small molecules (pills) like methotrexate, leflunomide, tofacitinib and injectable or infusable biologic therapies like abatacept, adalimumab, certolizumab, etanercept, golimumab, ri…
Rituximab bei ANCA-Vaskulitis: Premiere einer Transparenz-Studie – Deutsches Ärzteblatt
|
Rituximab bei ANCA-Vaskulitis: Premiere einer Transparenz-Studie
Deutsches Ärzteblatt Boston – Eine randomisierte Studie in einer eher seltenen klinischen Indikation könnte nicht nur den Betroffenen mit ANCA-assoziierter Vaskulitis nutzen, für die eine Behandlung mit dem Antikörper Rituximab die bessere Wahl sein könnte. Die Studie im … |
Pat's Place: Risk Versus Reward When Considering A Stem Cell Transplant – The Myeloma Beacon
|
Pat’s Place: Risk Versus Reward When Considering A Stem Cell Transplant
The Myeloma Beacon In last month’s column, I wrote about how much my perspective on myeloma therapy has changed over the past six years since my diagnosis. In a nutshell, I’m more willing to try new things and endure troubling side effects now than I was back when I was … |
Promising compound could offer new treatment for heart failure – Science Codex
|
Promising compound could offer new treatment for heart failure
Science Codex Heart failure occurs when the heart cannot pump enough blood to meet the body’s needs. It’s a very common condition, affecting about six million people in the United States, but current therapies are not adequately effective at improving health and … New designer compound treats heart failure by targeting cell nucleusMedical Xpress |
Rituximab therapy effective for ANCA-associated vasculitis – Phys.Org
Rituximab therapy effective for ANCA-associated vasculitisPhys.OrgIn an article published today in the New England Journal of Medicine, Immune Tolerance Network (ITN) researchers demonstrated that a single course of rituximab therapy (anti-CD20; Rituxa…
New Heart Failure Guidelines — They Just Get Better – Medscape
MedscapeNew Heart Failure Guidelines — They Just Get BetterMedscapeIt is an exciting month for us because the new guidelines for heart failure from the joint work of the American College of Cardiology Foundation and the American Heart Association have…